¿Cómo se compara el ratio PB de PAR con empresas similares?

PAR es un buen valor basado en su ratio Price-To-Book (4x) comparado con la media de empresas similares (6.9x).

¿Cómo se compara el ratio PB de PAR con el de otras empresas de la industria AU Biotechs ?

PAR es cara en función de su ratio Price-To-Book (4x) en comparación con la media de la industria Australian Biotechs (3.1x).

¿Cuál es el ratio PB de PAR comparado con su ratio PB justo? Este es el ratio PB esperado teniendo en cuenta las estimaciones de crecimiento de ingresos de la empresa, los márgenes de beneficios y otros factores de riesgo.

Datos insuficientes para calcular el ratio justo Price-To-Book de PAR para análisis de valoración.

¿Cuál es el precio justo de PAR si consideramos sus flujos de caja futuros? Para esta estimación utilizamos un modelo de flujo de caja descontado.

Datos insuficientes para calcular el valor justo de PAR para el análisis de valoración.

¿Cuál es la estimación de los analistas a 12 meses y, existe una confianza estadística en el precio objetivo de consenso?

El precio objetivo es más de 20% superior al precio actual de la acción, pero no hay suficientes analistas cubriendo la empresa para determinar [[confianza estadística]] de conformidad.

Paradigm Biopharmaceuticals (ASX:PAR) - Cotización, noticias y análisis

Resumen de acción PAR

Paradigm Biopharmaceuticals Limited se dedica a la investigación y desarrollo de productos terapéuticos para uso humano en Australia. Saber más

Análisis fundamental de PAR
Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	0/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Análisis de riesgos

Tiene menos de 1 año de cash runway

Tiene unos ingresos inferiores a 1 millón de dólares (A$0)

Los accionistas han sido diluidos en el último año

No tiene una capitalización de mercado significativa (A$98M)

+ 2 riesgos adicionales

Competidores de Paradigm Biopharmaceuticals Limited

Cynata Therapeutics

ASX:CYP

AU$38.4m

Beroni Group

NSX:BTG

AU$75.9m

Noxopharm

ASX:NOX

AU$30.7m

Dimerix

ASX:DXB

AU$186.6m

Historial de precios y rendimiento

Resumen de todos los máximos históricos, cambios y caídas de precios de Paradigm Biopharmaceuticals
Precios históricos de las acciones
Precio actual de la acción	AU$0.27
Máximo en las últimas 52 semanas	AU$0.48
Mínimo de 52 semanas	AU$0.17
Beta	0.87
1Cambio en 1 mes	25.58%
Variación en 3 meses	14.89%
Cambio de 1 año	-30.77%
3Variación en 3 años	-88.00%
Variación en 5 años	-93.11%
Variación desde la OPV	-27.03%

Noticias y actualizaciones recientes

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Rentabilidad de los accionistas

	PAR	AU Biotechs	Mercado AU
7D	10.2%	-3.6%	1.5%
1Y	-30.8%	10.0%	17.2%

Rentabilidad vs. Industria: Los resultados de PAR fueron inferiores a los de la industria Australian Biotechs, que obtuvo un rendimiento del 10% el año pasado.

Rentabilidad vs. Mercado: PAR obtuvo unos resultados inferiores a los del mercado Australian, que fueron del 17.2% el año pasado.

Volatilidad de los precios

Is PAR's price volatile compared to industry and market?
PAR volatility
PAR Average Weekly Movement	14.1%
Biotechs Industry Average Movement	9.7%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

Precio estable de las acciones: El precio de las acciones de PAR ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de PAR(14%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Australian.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited se dedica a la investigación y desarrollo de productos terapéuticos para uso humano en Australia. Su principal candidato es Zilosul, un polisulfato sódico de pentosano inyectable para el tratamiento de la artrosis, la mucopolisacaridosis, el virus del río Ross, el virus chikungunya, la insuficiencia cardiaca crónica, las enfermedades respiratorias alérgicas y el síndrome de dificultad respiratoria aguda. La empresa se constituyó en 2014 y tiene su sede en Melbourne (Australia).

Resumen de fundamentos de Paradigm Biopharmaceuticals Limited

¿Cómo se comparan los beneficios e ingresos de Paradigm Biopharmaceuticals con su capitalización de mercado?
Estadísticas fundamentales de PAR
Capitalización bursátil	AU$98.10m
Beneficios(TTM)	-AU$58.65m
Ingresos (TTM)	n/a

0.0x

Ratio precio-ventas (PS)

-1.6x

Ratio precio-beneficio (PE)

¿Está PAR sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de PAR
Ingresos	AU$0
Coste de los ingresos	AU$8.99k
Beneficio bruto	-AU$8.99k
Otros gastos	AU$58.64m
Beneficios	-AU$58.65m

Últimos beneficios comunicados

Jun 30, 2024

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.17
Margen bruto	0.00%
Margen de beneficio neto	0.00%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado PAR a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción PAR

Análisis de riesgos

Competidores de Paradigm Biopharmaceuticals Limited

ASX:CYP

AU$38.4m

NSX:BTG

AU$75.9m

ASX:NOX

AU$30.7m

ASX:DXB

AU$186.6m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium